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Abstract
Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid
(Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study
of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI)
participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined
presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to
CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males;
median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q);
Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11C-PiB-PET. Participants with an SUVR > 1.42
were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and
APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For
most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having
NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion,
MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ
burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both
cognitive and psychiatric symptoms.
Introduction
Neuropsychiatric symptoms (NPS) are risk factors for
mild cognitive impairment (MCI) and Alzheimer’s disease
(AD) dementia1–5. Furthermore, there is growing evi-
dence of an association between NPS and neuroimaging
biomarker abnormality in the context of brain aging.
Although some studies have examined the associations
between NPS, particularly depression and anxiety, and
cortical amyloid deposition among cognitively normal6–8
or impaired participants9–14, these studies have been
limited by small sample sizes, have not determined whe-
ther the associations between NPS and elevated brain
amyloid differ by cognitive status (cognitively unimpaired
(CU) vs. MCI), or have not conducted subanalyses among
persons with amnestic MCI (aMCI). aMCI coupled with
amyloid positivity is considered the typical prodromal
stage of dementia due to AD15.
We sought to examine the frequency of NPS among
community-dwelling non-demented participants (CU; MCI)
by brain amyloid status (abnormal, A+ vs. normal, A−). We
then investigated whether cognitive/amyloid status was
associated with the odds of having NPS. We also conducted
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secondary analyses among CU and aMCI participants. Based
on previous literature, we hypothesized that persons with
MCI and elevated amyloid burden would have higher odds
of having NPS as compared to MCI persons without ele-
vated amyloid burden or CU participants.
Materials and methods
Design and sample
This cross-sectional study was derived from the ongo-
ing, population-based Mayo Clinic Study of Aging
(MCSA) in Olmsted County, MN16. Eligible participants
were non-demented and ≥ 50 years of age, with a con-
current, valid NPS assessment and amyloid positron
emission tomography (PET) neuroimaging. The institu-
tional review boards of the Mayo Clinic and Olmsted
Medical Center in Rochester, MN approved the MCSA
protocols. All study participants provided written
informed consent.
Neurocognitive evaluation
Participants underwent a face-to-face evaluation
including a neurological examination, a study coordinator
visit, and neuropsychological testing. The reader is
referred elsewhere for details on the face-to-face evalua-
tion16. Briefly, the neurological evaluation comprised a
neurological history review, administration of the Short
Test of Mental Status17, and a neurological examination.
The study coordinator visit included the Clinical
Dementia Rating Scale (CDR)18. Neuropsychological
testing was administered by a psychometrist in order to
assess performance in four cognitive domains: memory
(delayed recall trials from Auditory Verbal Learning
Test19, Wechsler Memory Scale-Revised20, Logical
Memory and Visual Reproduction subtests), language
(Boston Naming Test21, category fluency22); visuospatial
skills (Wechsler Adult Intelligence Scale-Revised23, Pic-
ture Completion and Block Design subtests); and atten-
tion/executive function (Trail-Making Test Part B24,
Wechsler Adult Intelligent Scale-Revised23, Digit Symbol
Substitution subtest). An expert consensus panel con-
sisting of physicians, study coordinators, and neu-
ropsychologists reviewed the results for each participant
and determined whether a participant was CU or had
MCI based on published criteria. Individuals were classi-
fied as CU based on normative data developed in this
community25–28. For MCI, the revised Mayo Clinic cri-
teria for MCI29,30 were used: (1) cognitive concern
expressed by a physician, informant, participant, or nurse;
(2) impairment in one or more cognitive domains
(executive functions, memory, language, or visuospatial
skills); (3) essentially normal functional activities; and (4)
absence of dementia. Participants with MCI had a CDR
score of 0 or 0.5; however, the final diagnosis of MCI was
based on all available data.
Assessment of NPS
We measured NPS using the Neuropsychiatric Inven-
tory Questionnaire (NPI-Q)31. The NPI-Q is designed to
assess 12 emotional behaviors (i.e., agitation, delusion,
hallucination, depression, anxiety, euphoria, apathy, dis-
inhibition, irritability, aberrant motor behavior, sleep, and
eating/appetite) and was administered as a structured
interview to an informant by a research nurse or study
coordinator. In addition to the NPI-Q, participants
completed the Beck Depression Inventory-II (BDI-II)32
and Beck Anxiety Inventory (BAI)33. Both inventories are
validated and consist of 21 items that measure common
symptoms of depression (such as feeling guilty or loss of
interest) over the past 2 weeks and symptoms of anxiety
(such as nervousness or fear of losing control) over the
past 1 week. The severity of each symptom is rated on a
Likert scale ranging from 0 to 3, with a total score ranging
from 0 to 63 for BDI-II and BAI, respectively.
Molecular imaging: PiB-PET acquisition
We performed amyloid PET imaging using the Pitts-
burgh Compound B tracer. The reader is referred else-
where for details on PiB-PET imaging in the MCSA34,35.
Briefly, PiB scans, consisting of four 5-min dynamic
frames, were acquired from 40 to 60 min after intravenous
injection with 292–728MBq of 11C-PiB. Images were
analyzed using an in-house, fully automated image pro-
cessing pipeline in which image voxel values were
extracted from automatically labeled regions of interest
propagated from regions defined on each participant’s
own magnetic resonance imaging (MRI). A global amyloid
PET standardized uptake value ratio (SUVR) was formed
from the prefrontal, orbitofrontal, parietal, temporal,
anterior cingulate, and posterior cingulate/precuneus
regions of interest and normalized to the cerebellar gray
matter. Participants with an SUVR > 1.42 were classified
as having an abnormal PiB-PET retention (elevated β-
amyloid burden; A+) as we have previously validated by
autopsy36.
Statistical analysis
In this study, we created four groups based on cogni-
tive/amyloid status: (1) CU with normal amyloid deposi-
tion (CU/A−; n= 997); (2) CU with elevated brain
amyloid deposition (CU/A+; n= 446); (3) MCI with
normal amyloid deposition (MCI/A−; n= 78); and (4)
MCI with elevated brain amyloid deposition (MCI/A+;
n= 106). In a first step, we compared baseline char-
acteristics and frequency of NPS between these four
groups, using Kruskal–Wallis and Fisher’s Exact tests (for
continuous outcomes such as age; reported as median and
interquartile range (IQR)) and Chi-square tests (for
categorical outcomes such as male sex; reported as
number and percentage, %). We then used multivariable
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logistic regression models to compute odds ratios (OR)
and 95% confidence intervals (95% CIs) to compare the
odds of having NPS between these four groups. In
the regression analyses, we defined CU/A− persons as the
reference group. NPS were the presumed dependent
variables, and cognitive/amyloid status groups were the
presumed independent variables. We ran the regression
analyses on depression, anxiety, apathy, irritability,
nighttime behavior, any NPS, any non-psychotic NPS (all
measured through NPI-Q) and excluded other symptoms
measured by NPI-Q (i.e., agitation, motor behavior,
appetite/eating change, delusions, hallucinations,
euphoria, disinhibition, and any psychotic NPS) due to
low number of events. In order to examine the odds of
clinically significant depression and anxiety, we also
ran the analyses for BDI-II ≥ 13, BAI ≥ 8, and BAI ≥ 10.
Finally, we conducted secondary analyses comparing CU
(CU/A−; CU/A+) and amnestic MCI participants (aMCI/
A−; aMCI/A+). All analyses were adjusted for traditional
confounders, i.e., age, sex, education, as well as Apolipo-
protein (APOE) ε4 genotype status. Analyses were done
using the two-tailed alpha level of 0.05 and performed
with SAS 9.4 (SAS Institute, Cary, NC).
Results
Demographics
The sample consisted of 1627 persons (54.3% males).
The median (IQR) age was 72.7 (64.5, 79.3) years. Nine
hundred and ninety-seven participants were CU/A−, 446
CU/A+, 78 MCI/A−, and 106 were MCI/A+. Four
hundred and fifty-four participants (28.4%) were APOE ε4
carriers (Table 1). The MCI/A− group had a significantly
higher percentage of males compared to the other groups.
Participants who were MCI/A+ had the highest median
age, and participants who were CU/A− had the lowest
median age. For an overview of demographics for the CU
and aMCI sample, please refer to Supplementary Table 1.
Presence of NPS
The MCI/A+ group had the highest frequency of any
NPS (59.4%), followed by MCI/A− (34.6%), CU/A+
(24.9%), and CU/A− (20.0%; Table 2). Psychotic symp-
toms were rare across groups. The MCI/A+ group had
the highest frequency of persons with clinical depression
(BDI-II ≥ 13) and clinical anxiety (BAI ≥ 10). Similarly, in
the secondary analyses including aMCI and CU partici-
pants, the aMCI/A+ group had the highest frequency of
any NPS (59.3%), followed by aMCI/A− (35.7%), CU/A+
(24.9%), and CU/A− (20%). Please refer to Supplementary
Table 2 for display of data.
Association between NPS and cognitive/amyloid status
After adjusting for age, sex, education, and APOE ε4
carrier status, the odds of having any NPS as measured by
NPI-Q (i.e. depression, anxiety, apathy, irritability, night-
time behavior, any NPS, and any non-psychotic NPS),
depression (BDI-II ≥ 13), or anxiety (BAI ≥ 8, BAI ≥ 10)
were significantly increased for the MCI/A+ group as
compared to the reference group (CU/A−) for all vari-
ables (Table 3). MCI/A− participants had significantly
increased odds of having anxiety, apathy, irritability, any
NPS, any non-psychotic NPS, BAI ≥ 8, and BAI ≥ 10 as
compared to the reference group. In the secondary ana-
lyses including CU and aMCI participants, there was a
similar trend: aMCI/A+ participants, as compared to CU/
A−, had significantly increased odds of having NPS (all
Table 1 Demographic characteristics of study participants
CU/A− (n= 997) CU/A+ (n= 446) MCI/A− (n= 78) MCI/A+ (n= 106) Total
(n= 1627)
p
Male sex, N (%) 539 (54.1) 232 (52.0) 59 (75.6) 54 (50.9) 884 (54.3) 0.001a
Age, years 68.7 (61.3, 75.8) 77.2 (71.5, 82.1) 76.7 (69.3, 82.8) 81.3 (75.8, 86.0) 72.7 (64.5, 79.3) <0.001b
Age, N (%); years <0.001a
50–69 545 (54.7) 89 (20.0) 20 (25.6) 6 (5.7) 660 (40.6)
70–95 452 (45.3) 357 (80.0) 58 (74.4) 100 (94.3) 967 (59.4)
Education, years 15.0 (13.0, 16.0) 14.0 (12.0, 16.0) 12.0 (12.0, 16.0) 13.0 (12.0, 16.0) 14.0 (12.0, 16.0) <0.001b
> 12 years, N (%) 758 (76.0) 316 (70.9) 38 (48.7) 58 (54.7) 1170 (71.9) <0.001a
APOE ε4 carrier, N (%) 205 (21.0){19} 183 (41.5){5} 13 (17.1){2} 53 (50.5){1} 454 (28.4){27} <0.001a
Data presented are median (interquartile range) unless otherwise noted. Significant p values appear bold
CU cognitively unimpaired, MCI mild cognitive impairment, A− normal PiB-PET, A+ abnormal PiB-PET, APOE ε4 Apolipoprotein ε4, {N} number of missing data
aChi-Square test
bKruskal–Wallis test
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NPI-Q variables), depression (BDI-II ≥ 13), or anxiety
(BAI ≥ 8, BAI ≥ 10). For aMCI/A− participants, the odds
were significantly increased for irritability, any NPS, any
non-psychotic NPS, and BAI ≥ 8 (Supplementary Table 3).
Discussion
Here we report that community-dwelling older persons
with coexistence of MCI and elevated brain amyloid
deposition had significantly higher odds of having NPS as
Table 2 Frequency of neuropsychiatric symptoms across cognitive/amyloid status groups




Agitation 15 (1.5) 12 (2.7) 5 (6.4) 11 (10.4) 43 (2.6) <0.001d
Depression/dysphoria 100 (10.0) 51 (11.4) 10 (12.8) 31 (29.2) 192 (11.8) <0.001e
Anxiety 42 (4.2) 28 (6.3) 9 (11.5) 21 (19.8) 100 (6.1) <0.001e
Apathy 32 (3.2) 26 (5.8) 7 (9.0) 24 (22.6) 89 (5.5) <0.001e
Irritability 68 (6.8) 40 (9.0) 16 (20.5) 25 (23.6) 149 (9.2) <0.001e
Motor behavior 8 (0.8) 3 (0.7) 3 (3.8) 5 (4.7) 19 (1.2) 0.002d
Nighttime behaviora 40 (4.5) 32 (7.9) 5 (7.0) 17 (19.5) 94 (6.4) <0.001e
Appetite/eating change 31 (3.1) 14 (3.1) 3 (3.8) 16 (15.1) 64 (3.9) <0.001d
Psychotic NPS
Delusions 1 (0.1) 1 (0.2) 2 (2.6) 3 (2.8) 7 (0.4) <0.001d
Hallucinations 0 (0.0) 2 (0.4) 0 (0.0) 2 (1.9) 4 (0.2) 0.008d
Euphoria 4 (0.4) 3 (0.7) 0 (0.0) 1 (0.9) 8 (0.5) 0.591d
Disinhibition 10 (1.0) 2 (0.4) 3 (3.8) 7 (6.6) 22 (1.4) <0.001d
Number of NPS (0–12) <0.001f
Mean (SD) 0.4 (0.9) 0.5 (1.0) 0.8 (1.5) 1.5 (1.9) 0.5 (1.1)
Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 1.0 (0.0, 3.0) 0.0 (0.0, 0.0)
Any NPS 199 (20.0) 111 (24.9) 27 (34.6) 63 (59.4) 400 (24.6) <0.001e
Any non-psychotic NPS 199 (20.0) 111 (24.9) 27 (34.6) 63 (59.4) 400 (24.6) <0.001e
Any psychotic NPS 12 (1.2) 8 (1.8) 3 (3.8) 10 (9.4) 33 (2.0) <0.001d
BDI-II totalb <0.001f
Mean (SD) 4.1 (4.7) 4.6 (4.4) 4.9 (5.0) 7.5 (6.5) 4.5 (4.8)
Median (IQR) 3.0 (1.0, 6.0) 4.0 (1.0, 7.0) 3.0 (1.0, 8.0) 7.0 (2.0, 9.0) 3.0 (1.0, 7.0)
BDI-II ≥ 13b 54 (5.4) 28 (6.3) 8 (10.3) 17 (16.0) 107 (6.6) <0.001e
BAI total (0–63)c <0.001f
Mean (SD) 2.4 (3.7) 2.8 (4.3) 3.9 (5.2) 4.7 (5.5) 2.7 (4.1)
Median (IQR) 1.0 (0.0, 3.0) 1.0 (0.0, 4.0) 2.0 (0.0, 6.0) 3.0 (1.0, 7.0) 1.0 (0.0, 4.0)
BAI ≥ 8c 86 (8.6) 46 (10.3) 15 (19.2) 23 (21.7) 170 (10.5) <0.001e
BAI ≥ 10c 51 (5.1) 31 (7.0) 8 (10.3) 14 (13.2) 104 (6.4) 0.004e
Data presented are N (%) unless otherwise noted. Significant p values appear bold
CU cognitively unimpaired, MCI mild cognitive impairment, A− normal PiB-PET, A+ abnormal PiB-PET, SD standard deviation, IQR interquartile range, BDI-II Beck
Depression Inventory II, BAI Beck Anxiety Inventory
aInformation missing for 168 participants
bInformation missing for 5 participants
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compared to CU persons without elevated brain amyloid
deposition. For example, the odds of having apathy were
7.1 times higher in MCI/A+ than CU/A− persons.
Similarly, the odds for MCI/A+ as compared to CU/A−
persons of having anxiety were 5.3 times, of irritability 4.2
times, and of having depression 3.5 times higher. The
same observations hold true for aMCI persons in our
secondary analyses, i.e., the odds of having NPS for the
aMCI/A+ group were significantly higher than for the
reference group. Furthermore, on average, MCI/A− per-
sons had the second highest odds of having NPS, and the
odds were significantly increased for anxiety, apathy,
irritability, any NPS, any non-psychotic NPS, BAI ≥ 8, and
BAI ≥ 10 as compared to the reference group (CU/A−).
These results changed slightly when we looked at aMCI/A
− vs. CU/A− persons; only the increased odds for irrit-
ability, any NPS, any non-psychotic NPS, and BAI ≥ 8
remained significant. Furthermore, we additionally
adjusted the analyses for global cognition (z-score) to see
whether this would impact the findings. Indeed, we
observed that the odds for MCI/A+ participants were still
significantly increased for depression, anxiety, apathy,
irritability, any NPS, any non-psychotic NPS, and BDI-
II ≥ 13 but no longer remained significantly increased for
nighttime behavior, BAI ≥ 8, and BAI ≥ 10 (data not
shown). Similarly, the odds were still significantly
increased for MCI/A− for irritability and BAI ≥ 8 but no
longer for anxiety, apathy, any NPS, any non-psychotic
NPS, and BAI ≥ 10 (data not shown).
Overall, our results were in line with our hypothesis that
the combined presence of cognitive impairment and ele-
vated brain amyloid deposition is associated with greater
odds of having NPS as compared to MCI without amyloid
deposition. This indicates that the underlying AD biology
as measured by PET Aβ imaging contributes to an
increased frequency of NPS over and above expected from
MCI status alone, which implies that the underlying AD
biology may drive both the cognitive symptoms and






N OR (95% CI) p
Depression 97 CU/A− 978 1.00 (reference)
51 CU/A+ 441 1.13 (0.76, 1.67) 0.55
10 MCI/A− 76 1.33 (0.65, 2.72) 0.43
31 MCI/A+ 105 3.48 (2.05, 5.90) <0.001
Anxiety 42 CU/A− 978 1.00 (reference)
27 CU/A+ 441 1.45 (0.84, 2.50) 0.18
9 MCI/A− 76 2.82 (1.27, 6.25) 0.011
21 MCI/A+ 105 5.29 (2.73, 10.23) <0.001
Apathy 31 CU/A− 978 1.00 (reference)
26 CU/A+ 441 1.62 (0.90, 2.91) 0.11
7 MCI/A− 76 2.51 (1.03, 6.09) 0.042
24 MCI/A+ 105 7.06 (3.59, 13.88) <0.001
Irritability 68 CU/A− 978 1.00 (reference)
39 CU/A+ 441 1.32 (0.84, 2.08) 0.23
16 MCI/A− 76 3.39 (1.80, 6.38) <0.001
25 MCI/A+ 105 4.21 (2.34, 7.58) <0.001
Nighttime
behavior
39 CU/A− 879 1.00 (reference)
31 CU/A+ 400 1.31 (0.77, 2.23) 0.32
5 MCI/A− 69 1.13 (0.42, 3.06) 0.81
17 MCI/A+ 87 3.06 (1.52, 6.17) 0.002
Any NPS 192 CU/A− 978 1.00 (reference)
110 CU/A+ 441 1.18 (0.88, 1.58) 0.27
26 MCI/A− 76 1.77 (1.06, 2.97) 0.029
63 MCI/A+ 105 4.84 (3.06, 7.65) <0.001
Any non-
psychotic NPS
192 CU/A− 978 1.00 (reference)
110 CU/A+ 441 1.18 (0.88, 1.58) 0.27
26 MCI/A− 76 1.77 (1.06, 2.97) 0.029
63 MCI/A+ 105 4.84 (3.06, 7.65) <0.001
BDI-II ≥ 13 53 CU/A− 977 1.00 (reference)
28 CU/A+ 438 1.29 (0.77, 2.17) 0.33
8 MCI/A− 76 1.70 (0.75, 3.87) 0.20
17 MCI/A+ 105 3.42 (1.75, 6.71) <0.001
BAI ≥ 8 83 CU/A− 977 1.00 (reference)
45 CU/A+ 440 1.22 (0.80, 1.86) 0.35
15 MCI/A− 76 2.88 (1.52, 5.44) 0.001






N OR (95% CI) p
BAI ≥ 10 50 CU/A− 977 1.00 (reference)
30 CU/A+ 440 1.45 (0.86, 2.43) 0.16
8 MCI/A− 76 2.31 (1.02, 5.26) 0.045
14 MCI/A+ 105 3.01 (1.47, 6.15) 0.003
Significant p values appear bold. Analyses adjusted for age, sex, education, and
APOE ε4 genotype status
CU cognitively unimpaired, MCI mild cognitive impairment, A− normal PiB-PET,
A+ abnormal PiB-PET, OR odds ratio, CI confidence interval, p value comparing
to reference group, BDI-II Beck Depression Inventory II, BAI Beck Anxiety
Inventory
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psychiatric symptoms. Of note, 78 of our participants
were MCI/A-. The widely held interpretation is that the
underlying neurobiological substrate of an amyloid
negative MCI is most likely to be non-AD; whereas MCI
with abnormal amyloid is interpreted as MCI due to
AD37. In addition, even though the MCI/A+ group was
about 10 years older than the CU/A− group, our findings
are over and above what can be explained by age since we
have rigorously adjusted for age.
Our findings should also be interpreted within the
context of published literature. We and others have pre-
viously reported cross-sectional associations between
NPS, particularly depression, anxiety, and apathy, with
increased amyloid deposition in cognitively normal6,8 or
cognitively impaired persons10,11, whereas few studies
found no association9 or only in subgroup analyses7. To
our knowledge, there is only a limited number of cross-
sectional studies that examined the association between
NPS and cortical amyloid in both cognitively normal and
cognitively impaired persons. French researchers reported
that, in a sample comprised of CU persons as well as MCI
and AD patients, anxiety and irritability were associated
with higher cortical amyloid deposition in various regions
of interest; the number of significant correlations was
reduced in subgroup analyses among MCI or AD only12.
Similarly, researchers from UCLA observed that the
relationship between depression and anxiety with amyloid
deposition varied between cognitively normal and MCI
persons, i.e., depression and anxiety in MCI were asso-
ciated with amyloid deposition in different regions of
interest than in cognitively normal persons13. Finally, a
group of investigators from Pittsburgh found that PiB
retention in three out of six depressed MCI patients was
comparable to PiB retention in AD patients14. However,
these studies differ from ours in various ways, i.e., our
study had a larger, population-based sample, and we
wanted to know whether combined presence of cognitive
impairment and abnormal amyloid deposition was asso-
ciated with the odds of having NPS. Our study is also in
line with a recently published longitudinal study from
Harvard Medical School reporting that higher amyloid
beta burden was associated with increasing anxious-
depressive symptoms over time in cognitively normal
older individuals38. Our current study may also be rele-
vant to the ISTAART-AA criteria for mild behavioral
impairment (MBI) and the recently published MBI
checklist (MBI-C)39. The construct of MBI refers to a
change in behavior or personality in persons without
dementia aged ≥ 50 years that may be the case in a
majority of our study population.
The strengths of our study are the large-scale,
population-based sample and the rigorous acquisition of
NPS using three validated assessments that are widely
used in aging research. The limitations pertain to the
relatively small number of participants reporting NPS.
However, this was expected given that participants are
community-dwelling individuals aged ≥ 50 years and
similar frequencies of NPS in community-based samples
have been reported by our group and others in the
past40,41. Owing to the low number, we were not able to
conduct regression analyses stratified by APOE ε4 status,
but we adjusted our analyses for this potential con-
founder. Furthermore, in order to avoid an assumption
violation of the logistic regression, we did not run the
analyses on all NPS that are listed in Table 2 and Sup-
plementary Table 2, i.e., we excluded agitation, motor
behavior, appetite change, delusions, hallucinations,
euphoria, disinhibition, and any psychotic NPS due to low
number of events. Another limitation is that we did not
take into account the severity of NPS as assessed by the
NPI-Q and instead only examined the presence vs.
absence of symptoms. However, we included clinical
depression and anxiety as measured by BDI-II (score ≥ 13)
and BAI (score ≥ 8; score ≥ 10) in our analyses,
even though the scales do not take into consideration
whether the symptoms are acute or chronic. For example,
a person who has recurrent depression and is successfully
treated with antidepressant medication may be symptom-
free within 2 weeks of completing the BDI-II ques-
tionnaire. We also did not include or adjust the analyses
for other neuroimaging biomarkers such as structural
MRI of hippocampal volumes and frontal/global cortical
atrophy, and we did not investigate various regions of
interest but rather a global amyloid PET SUVR. In addi-
tion, we did not adjust our analyses for multiple com-
parisons. However, when considering a Bonferroni
correction for Table 3, the alpha significance level would
be 0.00167 (i.e., 0.05/30 since we have a total of 10 models
with 3 comparisons per model). Thus 10 out of the
17 significant p values still remain significant and none of
our major conclusions are affected by the correction.
Finally, given the cross-sectional nature of our study, the
direction of causality between NPS with amyloid and
cognitive status cannot be determined. The current study
did not investigate underlying mechanisms that may
explain the association between cognitive/amyloid status
with NPS. We and others have previously proposed
potential mechanisms linking NPS with cognitive out-
comes and neuroimaging biomarkers, such as etiologic
pathway, shared risk factor or confounding, reverse
causality, and/or interaction42,43.
Our cross-sectional data show that community-dwelling
persons with combined presence of MCI and amyloid
positivity as measured by PiB-PET are at significantly
Krell-Roesch et al. Translational Psychiatry           (2019) 9:123 Page 6 of 8
increased risk of having NPS. These findings add valuable
information on the association between NPS and cogni-
tive/amyloid status. Furthermore, they underline the
importance of a thorough assessment as well as potential
treatment of NPS in the clinical practice, particularly
among persons with confirmed neuroimaging biomarker
abnormality who are at risk for AD. The findings need to
be confirmed by a prospective cohort study.
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